Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Eledon Pharmaceuticals Inc
NASDAQ ELDN
Data sourced from
and
and
Download Data
Eledon Pharmaceuticals Inc Price to Sales Ratio (P/S) on June 03, 2024
Eledon Pharmaceuticals Inc Price to Sales Ratio (P/S) is NA on June 03, 2024, a NA change year over year. The price to sales ratio compares the market price per share of a company's stock to its sales revenue per share. It is calculated by dividing the market capitalization by the revenue, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's sales revenue. A higher ratio suggests that investors are willing to pay a higher price for each unit of sales revenue, indicating positive market sentiment and expectations for future revenue growth.
-
Eledon Pharmaceuticals Inc 52-week high Price to Sales Ratio (P/S) is NA on June 03, 2024, which is NA below the current Price to Sales Ratio (P/S).
-
Eledon Pharmaceuticals Inc 52-week low Price to Sales Ratio (P/S) is NA on June 03, 2024, which is NA below the current Price to Sales Ratio (P/S).
-
Eledon Pharmaceuticals Inc average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ELDN
| CEO | Dr. David-Alexandre C. Gros M.D., Ph.D. |
| IPO Date | Sept. 17, 2014 |
| Location | United States |
| Headquarters | 19900 MacArthur Boulevard, Irvine, CA, United States, 92612 |
| Employees | 20 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for kidney transplantation, xenotransplantation, and liver transplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
Acumen Pharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email